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Background:  Hyperlipidemia and ceramide accumulation are significant factors in cardiovascular disease, contributing to atherosclerosis 
and lipotoxic cardiomyopathy. The adipose-derived circulating factor adiponectin, as well as sphingosine 1-phosphate (S1P), may function 
to limit the harmful effects of ectopic lipid deposition in the heart. We previously demonstrated that adiponectin promotes an increase in 
ceramidase activity leading to ceramide catabolism and S1P generation. Here, we hypothesized that adiponectin can rescue lipotoxic 
cardiomyopathy by regulation of this ceramide:S1P rheostat.
methods:  We engineered transgenic mice with cardiomyocyte-specific over-expression of LPL-GPI, a model of lipotoxic cardiomyopathy, 
that additionally harbored a cardiomyocyte-specific adiponectin transgene (alpha-MHC promoter). We also engineered LPL-GPI knockout 
mice harboring an inactivated gene coding for adiponectin. Ventricular size and function were assessed noninvasively by echocardiography 
at 15 weeks of age.
results:  Over-expression of adiponectin improved ventricular systolic function (fractional shortening) by 20.1% (±10.4%, n=9, p<0.05 vs 
LPL-GPI control). LVID decreased 30.6% (±7.6%, n=9, p<0.05). Adiponectin over-expression was associated with reduction in ceramide 
and hexosylceramide levels by 33.4% and 40.6%, respectively (±10.2, n=6, p<0.05; ±6.3, n=6, P<0.005 both vs LPL-control), and a 
36.6% (±13.3%, n=3, p<0.05 vs LPL-control) increase in S1P levels. These changes were associated with robust rescue of cardiovascular 
mortality at 15 months (60%, n=12, p<0.01). These cardioprotective effects were not seen in adiponectin knockouts.
conclusion:  Adiponectin inhibits cardiac ceramide accumulation, promotes S1P formation, rescues cardiac function, and improves 
cardiovascular mortality in a model of lipotoxic cardiomyopathy. Together, these data suggest that manipulation of adiponectin is a novel 
means of treating lipotoxic heart disease.
